Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases
ABSTRACT Background The optimal management strategy for Stage IV rectal cancer with potentially treatable liver metastases remains controversial, particularly regarding the role of pelvic radiotherapy (RT). Aims We intend to investigate the impact of pelvic RT on oncological outcomes of rectal cance...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70122 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577748765245440 |
|---|---|
| author | Yayu Huang Genwen Chen Xian Zhang Yang Qian Jian Wang |
| author_facet | Yayu Huang Genwen Chen Xian Zhang Yang Qian Jian Wang |
| author_sort | Yayu Huang |
| collection | DOAJ |
| description | ABSTRACT Background The optimal management strategy for Stage IV rectal cancer with potentially treatable liver metastases remains controversial, particularly regarding the role of pelvic radiotherapy (RT). Aims We intend to investigate the impact of pelvic RT on oncological outcomes of rectal cancer with potentially treatable liver metastasis. Methods and Results This retrospective study included 83 patients diagnosed with rectal cancer and synchronous liver metastases from June 2012 to January 2022. All patients underwent radical surgery for rectal cancer and treatment of synchronous liver metastases, as determined by a multidisciplinary team (MDT). We divided the 83 patients into two treatment groups: chemoradiotherapy and surgery (CRT + S) and chemotherapy and surgery (C + S). The CRT + S group (n = 40) received pelvic RT, systemic therapy, and liver metastasis treatment. The C + S group (n = 43) received systemic therapy and liver metastasis treatment only. A total of 83 patients were analyzed with a median follow‐up of 45 months (range 12–127 months). In the CRT + S group, 48.2% (40/83) of patients underwent chemoradiotherapy, while the C + S group comprised 51.8% (43/83) of patients who received chemotherapy only. The CRT + S group demonstrated significantly longer local recurrence‐free survival compared to the C + S group (median 37.5 vs. 34 months; p = 0.011). In addition, patients in the CRT + S group had a longer median overall survival (OS) compared to the C + S group (46.50 vs. 44.0 months; p = 0.0497). Notably, achieving no evidence of disease (NED) status after definitive treatment for both primary and liver metastases was associated with improved OS (p = 0.008). Conclusion This study suggests that the addition of pelvic RT to multimodality therapy for patients with rectal cancer and potentially treatable liver metastases may improve local control and long‐term survival. The findings support the consideration of RT in the clinical management of this patient population. |
| format | Article |
| id | doaj-art-7674dd0702cf4cb19d887d5938c6ebcc |
| institution | Kabale University |
| issn | 2573-8348 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-7674dd0702cf4cb19d887d5938c6ebcc2025-01-30T15:46:35ZengWileyCancer Reports2573-83482025-01-0181n/an/a10.1002/cnr2.70122Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver MetastasesYayu Huang0Genwen Chen1Xian Zhang2Yang Qian3Jian Wang4Department of Radiation Oncology Zhongshan Hospital (Xiamen), Fudan University Xiamen ChinaDepartment of Radiation Oncology Zhongshan Hospital, Fudan University Shanghai ChinaDepartment of Radiation Oncology Zhongshan Hospital, Fudan University Shanghai ChinaDepartment of Radiation Oncology Zhongshan Hospital, Fudan University Shanghai ChinaDepartment of Radiation Oncology Zhongshan Hospital, Fudan University Shanghai ChinaABSTRACT Background The optimal management strategy for Stage IV rectal cancer with potentially treatable liver metastases remains controversial, particularly regarding the role of pelvic radiotherapy (RT). Aims We intend to investigate the impact of pelvic RT on oncological outcomes of rectal cancer with potentially treatable liver metastasis. Methods and Results This retrospective study included 83 patients diagnosed with rectal cancer and synchronous liver metastases from June 2012 to January 2022. All patients underwent radical surgery for rectal cancer and treatment of synchronous liver metastases, as determined by a multidisciplinary team (MDT). We divided the 83 patients into two treatment groups: chemoradiotherapy and surgery (CRT + S) and chemotherapy and surgery (C + S). The CRT + S group (n = 40) received pelvic RT, systemic therapy, and liver metastasis treatment. The C + S group (n = 43) received systemic therapy and liver metastasis treatment only. A total of 83 patients were analyzed with a median follow‐up of 45 months (range 12–127 months). In the CRT + S group, 48.2% (40/83) of patients underwent chemoradiotherapy, while the C + S group comprised 51.8% (43/83) of patients who received chemotherapy only. The CRT + S group demonstrated significantly longer local recurrence‐free survival compared to the C + S group (median 37.5 vs. 34 months; p = 0.011). In addition, patients in the CRT + S group had a longer median overall survival (OS) compared to the C + S group (46.50 vs. 44.0 months; p = 0.0497). Notably, achieving no evidence of disease (NED) status after definitive treatment for both primary and liver metastases was associated with improved OS (p = 0.008). Conclusion This study suggests that the addition of pelvic RT to multimodality therapy for patients with rectal cancer and potentially treatable liver metastases may improve local control and long‐term survival. The findings support the consideration of RT in the clinical management of this patient population.https://doi.org/10.1002/cnr2.70122liver metastaseslocal controlno evidence of disease (NED)radiotherapyrectal cancer |
| spellingShingle | Yayu Huang Genwen Chen Xian Zhang Yang Qian Jian Wang Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases Cancer Reports liver metastases local control no evidence of disease (NED) radiotherapy rectal cancer |
| title | Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases |
| title_full | Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases |
| title_fullStr | Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases |
| title_full_unstemmed | Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases |
| title_short | Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases |
| title_sort | pelvic radiotherapy in rectal cancer patients with synchronous potentially treatable liver metastases |
| topic | liver metastases local control no evidence of disease (NED) radiotherapy rectal cancer |
| url | https://doi.org/10.1002/cnr2.70122 |
| work_keys_str_mv | AT yayuhuang pelvicradiotherapyinrectalcancerpatientswithsynchronouspotentiallytreatablelivermetastases AT genwenchen pelvicradiotherapyinrectalcancerpatientswithsynchronouspotentiallytreatablelivermetastases AT xianzhang pelvicradiotherapyinrectalcancerpatientswithsynchronouspotentiallytreatablelivermetastases AT yangqian pelvicradiotherapyinrectalcancerpatientswithsynchronouspotentiallytreatablelivermetastases AT jianwang pelvicradiotherapyinrectalcancerpatientswithsynchronouspotentiallytreatablelivermetastases |